Press release
Anorexia Nervosa Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Therapies, Medication, Mechanism of Action, Route of Administration, and Companies by DelveInsight
(Albany, USA) As per DelveInsight's assessment, globally, several major pharma and biotech companies are working on various pipeline therapies in the Anorexia Nervosa therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years."Anorexia Nervosa Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Anorexia Nervosa Therapeutics Market.
The report provides a detailed description of the Anorexia Nervosa drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Anorexia Nervosa Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/anorexia-nervosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Anorexia Nervosa Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Anorexia Nervosa therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anorexia Nervosa treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Anorexia Nervosa drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Anorexia Nervosa treatment market.
Learn More about the Clinical and Commercial Development Activities in the Anorexia Nervosa Therapeutics Domain @
https://www.delveinsight.com/report-store/anorexia-nervosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Anorexia Nervosa Therapeutics Analysis
Several prominent companies are currently engaged in the development of therapies for Anorexia Nervosa. Notably, among these companies, COMPASS Pathways stands out for having progressed its Anorexia Nervosa drug candidates to the most advanced stage of clinical trials, namely Phase III. This phase marks a crucial stage in the drug development process, where the efficacy and safety of the treatment are rigorously evaluated in a larger population of patients. COMPASS Pathways' advancement to Phase III underscores the potential significance of their therapeutic approach in addressing the challenges posed by Anorexia Nervosa, reflecting the dedication and progress within the field of mental health research and treatment.
Anorexia Nervosa Companies in the Therapeutics Market Include:
• COMPASS Pathways
• Biomind Labs
And Many Others
Emerging and Marketed Anorexia Nervosa Therapies Covered in the Report Include:
• Psilocybin: COMPASS Pathways
Research into psilocybin therapy as a potential treatment for mental health issues is actively underway. This approach integrates the pharmacological properties of psilocybin, a psychoactive compound found in certain mushrooms commonly known as "magic mushrooms," with psychological support. In a phase II clinical trial, the company is currently assessing the effectiveness and safety of COMP360 psilocybin therapy specifically for individuals with anorexia nervosa.
Get an in-depth Assessment of the Emerging Therapies and Anorexia Nervosa Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/anorexia-nervosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Report Covers the Emerging Anorexia Nervosa Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Anorexia Nervosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Anorexia Nervosa Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/anorexia-nervosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Report Introduction
2. Executive Summary
3. Anorexia Nervosa Current Treatment Patterns
4. Anorexia Nervosa - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Anorexia Nervosa Late-Stage Products (Phase-III)
7. Anorexia Nervosa Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Anorexia Nervosa Discontinued Products
13. Anorexia Nervosa Product Profiles
14. Anorexia Nervosa Companies
15. Anorexia Nervosa Drugs
16. Dormant and Discontinued Products
17. Anorexia Nervosa Unmet Needs
18. Anorexia Nervosa Future Perspectives
19. Anorexia Nervosa Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/anorexia-nervosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Ashermans Syndrome Market: https://www.delveinsight.com/sample-request/ashermans-syndrome-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infection-absssi-market-insights-epidemiology-and-market-forecast
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Hepatitis D Market: https://www.delveinsight.com/report-store/hepatitis-d-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Chronic Plaque Psoriasis Market: https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
• Chronic Rhinosinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Epithelioid Sarcoma Market: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Acquired Hemophilia A Pipeline: https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Anal Cancer Market: https://www.delveinsight.com/report-store/anal-cancer-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Community-acquired Bacterial Pneumonia Market: https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market
• Familial Amyloid Polyneuropathy Market: https://www.delveinsight.com/report-store/familial-amyloid-polyneuropathy-transthyretin-amyloidosis-corino-de-andrades-disease-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anorexia Nervosa Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Therapies, Medication, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 3850033 • Views: …
More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…

Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…

Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…

Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Anorexia
Cancer Anorexia Market Expected to Reach USD 3.5 Billion by 2034
Cancer anorexia, often linked with cancer cachexia, is a debilitating condition characterized by loss of appetite, reduced food intake, and progressive weight loss in cancer patients. It is one of the most common and distressing cancer-related complications, affecting up to 80% of patients with advanced cancer. Beyond worsening quality of life, cancer anorexia contributes to poor treatment tolerance, faster disease progression, and higher mortality rates.
Download Full PDF Sample Copy of…
Cancer Anorexia Market to Reach USD 3.78 Billion by 2034
Cancer anorexia, also known as cancer-related anorexia or anorexia-cachexia syndrome (ACS), is a complex metabolic condition characterized by the loss of appetite and unintended weight loss in cancer patients. It affects up to 50-80% of advanced cancer cases, significantly impacting quality of life, treatment tolerance, and overall survival. While cancer anorexia is not a direct cause of cancer mortality, its complications contribute to increased morbidity and reduced treatment adherence.
Download Full…
Fighting Cancer Anorexia-Cachexia Syndrome: Global Market Insights 2024-2031
𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧:
Cancer Anorexia-Cachexia Syndrome (CACS) is a debilitating condition characterized by the loss of appetite, muscle wasting, and weight loss in cancer patients. Addressing this syndrome presents a significant challenge in oncology care. In the wake of the COVID-19 pandemic, understanding the dynamics of the global market for CACS drugs becomes paramount. This blog delves into the market size, share, and the impact of COVID-19, while exploring key factors shaping its…
Anorexia Memoirist is Dropping Jaws with Mind-Bending Debut Novel
Former Psychiatric Patient Takes Mental Illness For a Twisted and Utterly Gripping Spin In Her Amazon #1 New Release, Glass Half Broken
Having played both patient and practitioner, author Rachel Richards' unique experience of psychiatric disorders compelled her to write Glass Half Broken, a newly-released page-turner perfect for psychological suspense novel enthusiasts. Now available on Amazon.com, Glass Half Broken is a fast-paced domestic thriller packed with mystery and a shocking twist!
When…
Anorexia Nervosa Treatment Market Business Strategies, Developments and Opportun …
Global Anorexia Nervosa Treatment Market Research Report 2018 peaks the detailed analysis of industry share, growth factors, development trends, size, majors manufacturers and 2025 forecast. The report also analyzes innovative business strategies; value added factors and business opportunities. The Anorexia Nervosa Treatment report introduces market competition situation among the vendors and company profile, revenue, product & services, latest developments and business strategies.
Global Anorexia Nervosa Treatment market size will reach xx…
Research Focused On the Global Anorexia Nervosa Market 2017
MarketResearchReports.Biz presents this most up-to-date research on "Anorexia Nervosa-Pipeline Insights, 2017"
Anorexia Nervosa-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Anorexia Nervosa. The Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions,…